Abstract 18P
Background
Hormone receptor-positive (HR+)/human epidermal growth factor receptor 2 (HER2-) negative early breast cancers (eBCs) represent a significant health concern in the Indian population. Among premenopausal women with HR+ eBC, adjuvant ovarian function suppression (OFS) is considered as an integral component of treatment; however, its optimal utilization remains a subject of ongoing debate.
Methods
In response to identified gaps in clinical practice, a comprehensive questionnaire consisting of 28 statements was developed. These statements were reviewed and validated by a scientific committee, ensuring their accuracy and relevance to the study's objectives. A panel of 46 Indian experts and 1 global expert in the field of eBC were asked to rate their level of agreement/disagreement with each statement. Consensus was defined as achieving a ≥ 80% majority agreement among participants.
Results
Following two rounds of the modified Delphi technique, consensus was achieved on 19 out of 28 statements addressing critical aspects of premenopausal HR+ HER2- eBC management. The expert panel strongly recommends a comprehensive risk stratification approach for premenopausal HR+ HER2- eBC patients. Notably, Patients ≤40 years old are deemed high-risk candidates, recognizing age as an independent risk factor. For patients ≥40 years, a composite assessment incorporating clinicopathological factors (tumor grade, nodal involvement, and Ki67 score) is advised for risk assessment. For high-risk patients, OFS coupled with an Aromatase Inhibitor emerged as a recommended therapeutic strategy. The panel recommends a potential duration of up to 5 years for OFS, provided tolerability is maintained. In patients below 40 years of age, simultaneous initiation of OFS with chemotherapy is advised, while in those aged over 40 years, sequential initiation is deemed acceptable. Among the available LHRH agonists, Triptorelin stands out as the preferred choice, although the panel acknowledges similar efficacy across all options.
Conclusions
The outcomes of this consensus offer valuable guidance, enabling individualized and evidence-based approaches for OFS in Indian patients with HR+ HER2- eBC.
Clinical trial identification
Editorial acknowledgement
BioQuest Solutions Pvt Ltd.
Legal entity responsible for the study
Dr. Reddy's Laboratories.
Funding
Dr. Reddy's Laboratories.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
341P - NUP214 gene rearrangements in leukemia patients: Case series from a single institution
Presenter: Yu Jeong Choi
Session: Poster Display
Resources:
Abstract
344P - Venetoclax and azacitidine compared with azacitidine monotherapy for acute myeloid leukemia patients: A systematic review and meta-analysis
Presenter: Azzahra Noersamsjah
Session: Poster Display
Resources:
Abstract
345P - Safety and efficacy of platinum substitution in induction chemotherapy for mantle cell lymphoma
Presenter: Omali Pitiyarachchi
Session: Poster Display
Resources:
Abstract
346P - An assessment of marrow-infiltrating T cells in early relapsed hematologic cancer patients after allogeneic hematopoietic stem cell transplantation
Presenter: Ik-Chan Song
Session: Poster Display
Resources:
Abstract
347P - New targets for adult T cell leukemia/lymphoma (ATLL): A map for ATLL immunotherapy
Presenter: Zahra Rezaei Borojerdi
Session: Poster Display
Resources:
Abstract
348P - In-depth molecular analysis in the diagnosis of lymphomas with lymphoplasmacytic differentiation may provide a more precise diagnosis and rational treatment allocation
Presenter: Ella Willenbacher
Session: Poster Display
Resources:
Abstract
349P - Overall survival and progression-free survival comparison of lenalidomide + standard therapy versus standard therapy only in indolent lymphoma: A meta-analysis
Presenter: Kevin Winston
Session: Poster Display
Resources:
Abstract
350P - Intratumoural CD66b+ to predict treatment response in diffuse large B cell lymphoma (DLBCL)
Presenter: Mita Adriani
Session: Poster Display
Resources:
Abstract
351P - Clinical features and treatment outcomes of Waldenstrom macroglobulinemia patients: A single center study
Presenter: Devi Amelia
Session: Poster Display
Resources:
Abstract
352TiP - Randomized phase III study of daratumumab (D) versus bortezomib plus D as a maintenance therapy after D-MPB for elderly or non-elderly patients refusing transplant with untreated multiple myeloma (JCOG1911, B-DASH study)
Presenter: Tomotaka Suzuki
Session: Poster Display
Resources:
Abstract